Atorvastatin facilitates protection against contrast-induced nephropathy in patients undergoing coronary angiography via humoral mediators rather than altered renal hemodynamics.
作者信息
Wybraniec Maciej T, Filipecki Artur, Chudek Jerzy, Mizia-Stec Katarzyna
机构信息
First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Department of Pathophysiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
出版信息
Postepy Kardiol Interwencyjnej. 2018;14(2):191-194. doi: 10.5114/aic.2018.76412. Epub 2018 Jun 19.
Abstract
摘要
相似文献
1
Atorvastatin facilitates protection against contrast-induced nephropathy in patients undergoing coronary angiography via humoral mediators rather than altered renal hemodynamics.阿托伐他汀通过体液介质而非改变肾血流动力学，促进接受冠状动脉造影术患者预防造影剂肾病。
Postepy Kardiol Interwencyjnej. 2018;14(2):191-194. doi: 10.5114/aic.2018.76412. Epub 2018 Jun 19.
2
Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.短期大剂量阿托伐他汀预处理预防急性冠脉综合征行经皮冠状动脉介入治疗患者造影剂肾病（来自 ARMYDA-CIN [阿托伐他汀减少经皮冠状动脉介入治疗中造影剂肾病引起的心肌损伤]试验）。
Am J Cardiol. 2011 Jul 1;108(1):1-7. doi: 10.1016/j.amjcard.2011.03.001. Epub 2011 Apr 27.
3
Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography.短期或长期他汀类药物治疗对接受选择性冠状动脉造影患者造影剂所致肾功能损害的预防作用
Blood Coagul Fibrinolysis. 2010 Dec;21(8):750-7. doi: 10.1097/MBC.0b013e32834014a4.
4
Meta-analysis of short-term high versus low doses of atorvastatin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention.阿托伐他汀短期高剂量与低剂量预防冠状动脉造影/经皮冠状动脉介入治疗患者对比剂诱导急性肾损伤的荟萃分析。
J Clin Pharmacol. 2015 Feb;55(2):123-31. doi: 10.1002/jcph.411. Epub 2015 Jan 5.
5
Comparison of the efficacy of recombinant human brain natriuretic peptide with saline hydration in preventing contrast-induced nephropathy in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.重组人脑利钠肽与生理盐水水化预防接受冠状动脉造影术（无论是否同时进行经皮冠状动脉介入治疗）患者造影剂肾病疗效的比较
Int J Clin Exp Med. 2015 Aug 15;8(8):14166-72. eCollection 2015.
6
[Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress].
Nan Fang Yi Ke Da Xue Xue Bao. 2012 Nov;32(11):1600-2.
7
Atorvastatin and prevention of contrast induced nephropathy following coronary angiography.阿托伐他汀与冠状动脉造影术后对比剂诱导的肾病的预防
J Res Med Sci. 2015 Jan;20(1):1-6.
8
Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography.短期大剂量阿托伐他汀预防冠状动脉造影患者造影剂肾病的疗效。
Angiology. 2010 Oct;61(7):711-4. doi: 10.1177/0003319710364216. Epub 2010 Apr 14.
9
[Atorvastatin attenuated contrast induced renal function damage].阿托伐他汀减轻造影剂诱导的肾功能损害
Zhonghua Xin Xue Guan Bing Za Zhi. 2009 May;37(5):389-93.
10
Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).瑞舒伐他汀与阿托伐他汀预防接受直接经皮冠状动脉介入治疗患者的造影剂诱导肾病（ROSA-cIN试验）。
Acta Cardiol. 2013 Oct;68(5):489-94. doi: 10.1080/ac.68.5.2994472.
本文引用的文献
1
Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials.短期中等剂量或高剂量瑞舒伐他汀预防对比剂肾病的疗效：15项随机对照试验的荟萃分析
Medicine (Baltimore). 2017 Jul;96(27):e7384. doi: 10.1097/MD.0000000000007384.
2
Longitudinal Risk of Adverse Events in Patients With Acute Kidney Injury After Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry.经皮冠状动脉介入治疗后急性肾损伤患者不良事件的纵向风险：来自国家心血管数据登记处的见解
Circ Cardiovasc Interv. 2017 Apr;10(4). doi: 10.1161/CIRCINTERVENTIONS.116.004439.
3
Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro.阿托伐他汀通过上调Hsp27在体内和体外发挥抗凋亡作用，从而预防造影剂诱导的肾病。
Mol Med Rep. 2017 Apr;15(4):1963-1972. doi: 10.3892/mmr.2017.6251. Epub 2017 Feb 28.
4
Pre-procedural renal resistive index accurately predicts contrast-induced acute kidney injury in patients with preserved renal function submitted to coronary angiography.术前肾阻力指数可准确预测肾功能正常且接受冠状动脉造影的患者发生对比剂诱导的急性肾损伤。
Int J Cardiovasc Imaging. 2017 May;33(5):595-604. doi: 10.1007/s10554-016-1039-1. Epub 2016 Dec 19.
5
Urinary renalase concentration in patients with preserved kidney function undergoing coronary angiography.接受冠状动脉造影的肾功能正常患者的尿肾酶浓度
Nephrology (Carlton). 2018 Feb;23(2):133-138. doi: 10.1111/nep.12954.
6
Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis.12 种预防对比剂诱导急性肾损伤治疗策略的比较效果：系统评价和贝叶斯网络荟萃分析。
Am J Kidney Dis. 2017 Jan;69(1):69-77. doi: 10.1053/j.ajkd.2016.07.033. Epub 2016 Oct 1.
7
Atorvastatin attenuates contrast-induced nephropathy by modulating inflammatory responses through the regulation of JNK/p38/Hsp27 expression.阿托伐他汀通过调节JNK/p38/Hsp27表达来调控炎症反应，从而减轻造影剂诱导的肾病。
J Pharmacol Sci. 2016 May;131(1):18-27. doi: 10.1016/j.jphs.2016.03.006. Epub 2016 Mar 18.
8
Renalase does not catalyze the oxidation of catecholamines.肾酶不催化儿茶酚胺的氧化。
Arch Biochem Biophys. 2015 Aug 1;579:62-6. doi: 10.1016/j.abb.2015.05.016. Epub 2015 Jun 3.
9
Identification of a receptor for extracellular renalase.细胞外肾酶受体的鉴定
PLoS One. 2015 Apr 23;10(4):e0122932. doi: 10.1371/journal.pone.0122932. eCollection 2015.
10
Renalase protects against contrast-induced nephropathy in Sprague-Dawley rats.肾酶可保护Sprague-Dawley大鼠免受造影剂诱导的肾病。
PLoS One. 2015 Jan 30;10(1):e0116583. doi: 10.1371/journal.pone.0116583. eCollection 2015.
Zotero 插件